|Bid||0.3500 x 800|
|Ask||0.3504 x 800|
|Day's Range||0.3275 - 0.4401|
|52 Week Range||0.3275 - 1.9200|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
Vistagen, a thinly traded nanocap, said Thursday after the market open that topline results from an exploratory Phase 2 study of its investigational drug AV-101 did not demonstrate significant difference from placebo on the primary outcome measure. The drug, which is being evaluated as a monotherapy in patients with TRD, was studied for the change from baseline in the Hamilton Depression Rating Scale total score.
As an investor, mistakes are inevitable. But really bad investments should be rare. So spare a thought for the long term shareholders of VistaGen Therapeutics, Inc. (NASDAQ:VTGN); the share price is down a whopping 88% in the...
In what could be called an unexpected and pleasant surprise this week for Johnson & Johnson (JNJ), an FDA panel voted overwhelmingly in favor of approval for esketamine, trade name Spravato, for treatment-resistant depression (TRD). Warning! GuruFocus has detected 6 Warning Signs with GOLD. Esketamine is the molecular mirror image of the sedative ketamine, often prescribed off-label for severe cases of depression involving the risk of suicide.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
The big shareholder groups in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...